In Australia, heart failure affects over half a million individuals, making up over 150,000 hospitalisations per year, over 60,000 deaths, and a cost of over $3 billion. Globally, heart failure affects more than 60 million people and is the world’s leading cause of hospitalisation in people over 65 years. It makes up 17% of all
Read More
AI and medical technology firm Echo IQ Limited (ASX: EIQ) has inked a commercial licensing agreement with respiratory health MedTech company Respiri Limited (ASX: RSH) to incorporate Echo IQ’s EchoSolv cardiovascular decision support into Respiri’s remote patient monitoring (RPM) user base. As per the agreement, Respiri will integrate EchoSolv cardiovascular solutions into its U.S. Remote
Read More
“Coronary Artery Disease. We see you.” Quite literally, healthcare company Artrya (ASX: AYA) sees your heart disease through its artificial intelligence solution Salix, which uses AI imaging to detect the intensity of your heart disease and aims to leverage its tech to access a global market alongside another jab at its FDA approval. In June
Read More
Coronary heart disease is the most prevalent type of heart disease and the leading single cause of death in Australia, representing 11% of all deaths in 2018. 42% of coronary heart disease related deaths resulted from a heart attack. Medtech company Artrya (ASX: AYA) is working to improve diagnosis of this often silent disease. Their
Read More